Skip to content

Disc Medicine IRON Change in Lease Liabilities

Change in Lease Liabilities at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$547K-260%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$4.46M-10.2%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$3.49M-6.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$1.85M-26.0%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's change in lease liabilities?
Disc Medicine (IRON) reported change in lease liabilities of -$168K in Q1 2026.
How has Disc Medicine's change in lease liabilities changed year-over-year?
Disc Medicine's change in lease liabilities decreased by 138.6% year-over-year, from $435K to -$168K.
What is the long-term trend for Disc Medicine's change in lease liabilities?
Over 2 years (2021 to 2024), Disc Medicine's change in lease liabilities has grown at a 87.4% compound annual growth rate (CAGR), from -$141K to -$495K.
What does change in lease liabilities mean?
Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.